Minisha Sood
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1144420043
Payments from drug & device makers
Across 802 payments — averaging $113.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$56K
- Mannkind Corporation$15K
- AstraZeneca$8K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AbbVie$1K
- plus $7K from 46 others
What the payments were for
- Consulting fees$6,7137%
- Speaking & faculty fees$63,43370%
- Travel & lodging$3,5884%
- Food & beverage$16,79819%
- Education$900%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$35,703
- TOUJEO$22,071
- AFREZZA$14,201
- FARXIGA$6,542
- STEGLATRO$339
- Ozempic$125
- t:slim X2 insulin pump$110
How this compares
$90,681 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 110 | $131,009 |
| TymlosAbaloparatide | 18 | $85,007 |
| OzempicSemaglutide | 60 | $65,980 |
| JardianceEmpagliflozin | 39 | $39,008 |
| WegovySemaglutide | 11 | $13,730 |
| TrulicityDulaglutide | 12 | $13,697 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $12,410 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $9,232 |
| SynthroidLevothyroxine Sodium | 64 | $6,989 |
| TirosintLevothyroxine Sodium | 35 | $6,731 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,956 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 30 | $3,820 |
| Levothyroxine Sodium | 98 | $1,267 |
| Liothyronine Sodium | 26 | $1,027 |
| Metformin Hcl ErMetformin Hcl | 57 | $892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,472 | $144,705122 claims |
| Radius Health, Inc.Tymlos | $229 | $85,00718 claims |
| Novo NordiskOzempic, Wegovy | $1,710 | $79,71071 claims |
| Boehringer IngelheimJardiance | $111 | $39,00839 claims |
| AbbVieSynthroid | $1,439 | $6,98964 claims |
| IBSA Pharma Inc.Tirosint | $338 | $6,73135 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $266 | $1,26798 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.